Bifogade filer
Changes in the Revenio Group Corporation’s Leadership team
Kurs
+4,02%
Likviditet
0,79 MEUR
Prenumeration
Kalender
| Est. tid* | ||
| 2025-10-30 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-07 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-04-29 | - | Kvartalsrapport 2025-Q1 |
| 2025-04-11 | - | X-dag ordinarie utdelning REG1V 0.40 EUR |
| 2025-04-10 | - | Årsstämma |
| 2025-02-13 | - | Bokslutskommuniké 2024 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-08 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-25 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-05 | - | X-dag ordinarie utdelning REG1V 0.38 EUR |
| 2024-04-04 | - | Årsstämma |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-10 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-24 | - | X-dag ordinarie utdelning REG1V 0.36 EUR |
| 2023-03-23 | - | Årsstämma |
| 2023-02-09 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-04 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-11 | - | X-dag ordinarie utdelning REG1V 0.34 EUR |
| 2022-04-08 | - | Årsstämma |
| 2022-02-10 | - | Bokslutskommuniké 2021 |
| 2021-10-21 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-05 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-23 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-18 | - | X-dag ordinarie utdelning REG1V 0.32 EUR |
| 2021-03-17 | - | Årsstämma |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-10-22 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-06 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-09 | - | X-dag ordinarie utdelning REG1V 0.30 EUR |
| 2020-06-08 | - | Årsstämma |
| 2020-04-22 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-20 | - | Bokslutskommuniké 2019 |
| 2019-10-24 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-15 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-21 | - | X-dag ordinarie utdelning REG1V 0.28 EUR |
| 2019-03-20 | - | Årsstämma |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-10-25 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-06 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-20 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-21 | - | X-dag ordinarie utdelning REG1V 0.78 EUR |
| 2018-03-20 | - | Årsstämma |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
| 2017-10-26 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-07 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-22 | - | Årsstämma |
| 2017-04-20 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-23 | - | X-dag ordinarie utdelning REG1V 0.74 EUR |
| 2017-02-16 | - | Bokslutskommuniké 2016 |
| 2016-10-31 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-08 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-25 | - | Kvartalsrapport 2016-Q1 |
| 2016-03-16 | - | X-dag ordinarie utdelning REG1V 0.70 EUR |
| 2016-03-15 | - | Årsstämma |
| 2016-02-15 | - | Bokslutskommuniké 2015 |
| 2015-10-27 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-10 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-24 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-20 | - | X-dag ordinarie utdelning REG1V 0.45 EUR |
| 2015-03-19 | - | Årsstämma |
| 2015-02-12 | - | Bokslutskommuniké 2014 |
| 2014-10-21 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-04 | - | Kvartalsrapport 2014-Q2 |
| 2014-04-24 | - | Kvartalsrapport 2014-Q1 |
| 2014-03-21 | - | X-dag ordinarie utdelning REG1V 0.30 EUR |
| 2014-03-20 | - | Årsstämma |
| 2014-02-12 | - | Bokslutskommuniké 2013 |
| 2013-12-11 | - | X-dag bonusutdelning REG1V 0.3 |
| 2013-12-09 | - | Extra Bolagsstämma 2013 |
| 2013-10-22 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-28 | - | Kapitalmarknadsdag 2013 |
| 2013-08-05 | - | Kvartalsrapport 2013-Q2 |
| 2013-08-02 | - | X-dag bonusutdelning REG1V 0.12 |
| 2013-04-19 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-28 | - | Split REG1V 10:1 |
| 2013-03-22 | - | X-dag ordinarie utdelning REG1V 0.02 EUR |
| 2013-03-21 | - | Årsstämma |
| 2013-02-08 | - | Bokslutskommuniké 2012 |
| 2012-10-19 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-06 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-19 | - | Kvartalsrapport 2012-Q1 |
| 2012-03-29 | - | X-dag ordinarie utdelning REG1V 0.02 EUR |
| 2012-03-28 | - | Årsstämma |
| 2012-02-16 | - | Bokslutskommuniké 2011 |
| 2011-10-26 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-08 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-27 | - | Kvartalsrapport 2011-Q1 |
| 2011-04-01 | - | X-dag ordinarie utdelning REG1V 0.02 EUR |
| 2011-03-31 | - | Årsstämma |
| 2011-02-16 | - | Bokslutskommuniké 2010 |
| 2010-04-09 | - | X-dag ordinarie utdelning REG1V 0.01 EUR |
| 2009-04-16 | - | X-dag ordinarie utdelning REG1V 0.02 EUR |
| 2008-04-03 | - | X-dag ordinarie utdelning REG1V 0.04 EUR |
| 2007-04-09 | - | X-dag ordinarie utdelning REG1V 0.01 EUR |
| 2006-03-31 | - | X-dag ordinarie utdelning REG1V 0.00 EUR |
| 2005-04-01 | - | X-dag ordinarie utdelning REG1V 0.00 EUR |
| 2004-03-29 | - | X-dag ordinarie utdelning REG1V 0.00 EUR |
| 2003-03-24 | - | X-dag ordinarie utdelning REG1V 0.00 EUR |
| 2002-04-15 | - | X-dag ordinarie utdelning REG1V 0.00 EUR |
Beskrivning
| Land | Finland |
|---|---|
| Lista | Mid Cap Helsinki |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Revenio Group Corporation, Stock Exchange Release, October 4, 2022 at 3.30 pm (EEST)
Changes in the Revenio Group Corporation’s Leadership Team
Mika Salkola, Revenio Group Corporation's Vice President of Research, has retired as of 4 October 2022. Salkola has worked as a Director of Product Development and Research at iCare Finland Oy, a subsidiary of Revenio Group Corporation, since 2015, and has been a member of the Revenio Group’s Leadership team since 2018.
"I would like to thank Mika for his excellent work in his key role on iCare's product development, and for sharing his unique expertise to our product development team. Through his visionary work, the company has evolved into an innovative pioneer of eye disease screening and monitoring", says Jouni Toijala, CEO of Revenio.
M.Sc. Eng. Giuliano Barbaro, Vice President, Devices, will take over the responsibility for research management in addition to product development as of 4 October 2022. He has been a member of Revenio's Leadership team since 2020.
"This was a logical transition for Giuliano Barbaro to take on a broader product development portfolio. I am confident that Giuliano, with his strong product development and industry expertise, is the right person to lead Revenio's product development into a new era. His extensive experience in CenterVue S.p.A.'s demanding product development also supports Revenio's strong internationalization strategy", says CEO Jouni Toijala.
Revenio Group Oyj
Further information
CEO Jouni Toijala, tel. +358 50 484 0085
jouni.toijala@revenio.fi
Distribution
Nasdaq Helsinki Oy
Key media
www.revenio.fi
Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.
In 2021, the Group’s net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.